You are here

Article Text

Article menu
Download PDFPDF
DTB Select
MI risk associated with naproxen and diclofenac in spondyloarthritis

https://doi.org/10.1136/dtb.2018.000050

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Review of: Dunbreuil M et al. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. Ann Rheum Dis 2018;77:1137–42.

    Key learning points

    • NSAIDs are associated with an increased risk of thrombotic events.

    • Diclofenc has a less favourable cardiovascular risk profile compared with naproxen.

    • The risk of myocardial infarction associated with diclofenac was higher in people with spondyloarthritis than those with osteoarthritis.

    An analysis of the incidence of myocardial infarction (MI) in people with spondylarthritis (SpA) and osteoarthritis (OA) treated with NSAIDs provides further evidence that diclofenac is associated with a higher risk than naproxen.

    Overview

    This nested case–control study used medical records from a database of 11 million patients registered with UK general practices to assess the risk of MI among patients with SpA (ankylosing spondylitis or psoriatic arthritis) who were prescribed NSAIDs. The authors aimed to test the hypothesis that MI …

    View Full Text

    Footnotes

    • Provenance and peer review Commissioned; internally peer reviewed.

    • Contributors DTB Team.